A multi-center, single-dose, open-label, randomized, parallel group study to investigate the reduction of initial taspoglutide Cmax after administration of 20 mg taspoglutide 10% Sustained Release Formulation (SRF) using three modified formulations as compared to the current Phase 3 formulation in healthy volunteers. - Taspoglutide BE study in healthy volunteers

Hoffmann-La Roche0 个研究点目标入组 100 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Healthy male or female (Non child bearing potential)
•18-65 years of age, inclusive
•BMI >20 AND <<= 35 kg/m2
•Non-smoker, or not more than 10 cigarettes/day for at least six months before drug administration

•Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of having participated in more than 3 other drug studies (for men) / more than 2 other drug studies (for women) in the 10 months prior to the start of this study, or when having donated more than 1.5 liters of blood (for men) / more than 1.0 liters of blood (for women) in the 10 months prior to the start of this study

发起方